Involvement of insulin resistance in the protective effect of metformin against alcoholic liver injury

Alcoholism: Clinical and Experimental Research

Volumn 38, Issue 6, 2014, Pages 1510-1519

  Zhu, Zhantao ^a   Jiang, Zhian ^a   Zhou, Junying ^a   Zhou, Dongfang ^a   Wang, Wei ^a   Zhao, Caiyan ^a   Zhen, Zhen ^a   Nanji, Amin A ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Adenosine Monophosphate Activated Protein Kinase; Adiponectin; Ethanol; Insulin Resistance; Metformin

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENYLATE KINASE; ADIPONECTIN; ADIPONECTIN RECEPTOR 2; ALCOHOL; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FATTY ACID SYNTHASE; GLUCOSE; INSULIN; INSULIN RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 2, RAT; ANTIDIABETIC AGENT; PPARGC1A PROTEIN, RAT; TRANSCRIPTION FACTOR;

ALCOHOL LIVER CIRRHOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; LIVER; LIVER DISEASES, ALCOHOLIC; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ADIPONECTIN; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; LIVER DISEASES, ALCOHOLIC; MALE; METFORMIN; PPAR ALPHA; RATS, WISTAR; RECEPTORS, ADIPONECTIN; TRANSCRIPTION FACTORS;

EID: 84901923852     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.12418     Document Type: Article

References (45)

1. Adachi M, Brenner DA (2005) Clinical syndromes of alcoholic liver disease. Dig Dis 23:255-263.
2. Akcam M, Boyaci A, Pirgon O, Kaya S, Uysal S, Dundar BN (2011) Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. Int J Vitam Nutr Res 81:398-406.
3. Asensio-Lopez MC, Lax A, Pascual-Figal DA, Valdes M, Sanchez-Mas J (2011) Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. Free Radic Biol Med 51:1861-1871.
4. Beier JI, Arteel GE, McClain CJ (2011) Advances in alcoholic liver disease. Curr Gastroenterol Rep 13:56-64.
5. Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, Luyendyk JP, Roth RA, Arteel GE (2006) Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 130:2099-2112.
6. Bermudez V, Cano R, Cano C, Bermudez F, Leal E, Acosta K, Mengual E, Arraiz N, Briceno C, Gomez J, Bustamante M, Aparicio D, Cabrera M, Valdelamar L, Rodriguez M, Manuel V, Hernandez R (2008) Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes. Am J Ther 15:409-416.
7. Carling D, Thornton C, Woods A, Sanders Matthew J (2012) AMP-activated protein kinase: new regulation, new roles? Biochem J 445:11-27.
8. Chen G, Zhang Y, Lu D, Li NQ, Ross AC (2009) Retinoids synergize with insulin to induce hepatic Gck expression. Biochem J 419:645-653.
9. Crabb DW, Liangpunsakul S (2006) Alcohol and lipid metabolism. J Gastroenterol Hepatol 21:S56-S60.
10. Fischer M, You M, Matsumoto M, Crabb DW (2003) Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 278:27997-28004.
11. Grant BF, Dufour MC, Harford TC (1988) Epidemiology of alcoholic liver disease. Semin Liver Dis 8:12-25.
12. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, Hardie DG (1996) Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 271:27879-27887.
13. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125-1131.
14. Layne AS, Nasrallah S, South MA, Howell ME, McCurry MP, Ramsey MW, Stone MH, Stuart CA (2011) Impaired muscle AMPK activation in the metabolic syndrome may attenuate improved insulin action after exercise training. J Clin Endocrinol Metab 96:1815-1826.
15. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, Wierzbicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zang M (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13:376-388.
16. Liangpunsakul S, Wou SE, Zeng Y, Ross RA, Jayaram HN, Crabb DW (2008) Effect of ethanol on hydrogen peroxide-induced AMPK phosphorylation. Am J Physiol Gastrointest Liver Physiol 295:G1173-G1181.
17. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM (2000) Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6:998-1003.
18. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737.
19. McKim SE, Gabele E, Isayama F, Lambert JC, Tucker LM, Wheeler MD, Connor HD, Mason RP, Doll MA, Hein DW, Arteel GE (2003) Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterology 125:1834-1844.
20. de la Monte SM, Yeon JE, Tong M, Longato L, Chaudhry R, Pang MY, Duan K, Wands JR (2008) Insulin resistance in experimental alcohol-induced liver disease. J Gastroenterol Hepatol 23:e477-e486.
21. Nanji AA, Dannenberg AJ, Jokelainen K, Bass NM (2004) Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation. J Pharmacol Exp Ther 310:417-424.
22. Nanji AA, Jokelainen K, Fotouhinia M, Rahemtulla A, Thomas P, Tipoe GL, Su GL, Dannenberg AJ (2001) Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines. Am J Physiol Gastrointest Liver Physiol 281:G1348-G1356.
23. Nanji AA, Khettry U, Sadrzadeh SM, Yamanaka T (1993) Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. Am J Pathol 142:367-373.
24. Pang M, de la Monte SM, Longato L, Tong M, He J, Chaudhry R, Duan K, Ouh J, Wands JR (2009) PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol 50:1192-1201.
25. Patel BC, D'Arville C, Iwahashi M, Simon FR (1991) Impairment of hepatic insulin receptors during chronic ethanol administration. Am J Physiol 261:G199-G205.
26. Rabe K, Lehrke M, Parhofer KG, Broedl UC (2008) Adipokines and insulin resistance. Mol Med 14:741-751.
27. Rehm J, Samokhvalov AV, Shield KD (2013) Global burden of alcoholic liver diseases. J Hepatol 59: 160-168.
28. Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS (2012) AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res 53: 2490-2514.
29. Stein SC, Woods A, Jones NA, Davison MD, Carling D (2000) The regulation of AMP-activated protein kinase by phosphorylation. Biochem J 3:437-443.
30. Tangeman L, Wyatt CN, Brown TL (2012) Knockdown of AMP-activated protein kinase alpha 1 and alpha 2 catalytic subunits. J RNAi Gene Silencing 8:470-478.
31. Tankova T (2003) Current indications for metformin therapy. Rom J Intern Med 41:215-225.
32. Tilg H, Day CP (2007) Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol 4:24-34.
33. Tomita K, Tamiya G, Ando S, Kitamura N, Koizumi H, Kato S, Horie Y, Kaneko T, Azuma T, Nagata H, Ishii H, Hibi T (2005) AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats. Alcohol Clin Exp Res 29:240S-245S.
34. Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100:328-341.
35. Tuma DJ, Casey CA, Sorrell MF (1991) Chronic ethanol-induced impairments in receptor-mediated endocytosis of insulin in rat hepatocytes. Alcohol Clin Exp Res 15:808-813.
36. Winder WW, Hardie DG (1999) AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 277:E1-E10.
37. Xiao X, Song BL (2013) SREBP: a novel therapeutic target. Acta Biochim Biophys Sin 45:2-10.
38. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112:91-100.
39. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295.
40. Yao XH, Chen L, Nyomba BL (2006) Adult rats prenatally exposed to ethanol have increased gluconeogenesis and impaired insulin response of hepatic gluconeogenic genes. J Appl Physiol 100:642-648.
41. You M, Considine RV, Leone TC, Kelly DP, Crabb DW (2005) Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 42:568-577.
42. You M, Crabb DW (2004) Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins. Alcohol 34:39-43.
43. You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW (2004) The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 127:1798-1808.
44. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174.
45. Zhou JY, Jiang ZA, Zhao CY, Zhen Z, Wang W, Nanji AA (2013) Long-term binge and escalating ethanol exposure causes necroinflammation and fibrosis in rat liver. Alcohol Clin Exp Res 37:213-222.